ESBL and MBL Mediated Resistance in
Pseudomonas aeruginosa: An Emerging
Threat to Clinical Therapeutics
1552-1554
Correspondence
Basavaraj Virupakshappa Peerapur
MD (Microbiology) Prof and head Department of Microbiology,
BLDEU’s Shri B M Patil Medical college Bijapur,
Karnataka, India.
Phone: 09448139438
E-mail: peerapur_2003@yahoo.co.in
Purpose: The present study was undertaken to detect the extended spectrum β lactamases (ESBL) and metallo β lactamases (MBL) in isolates of Pseudomonas aeruginosa which were isolated from wound infections and to evaluate their susceptibility patterns.
Materials and Methods: One hundred and twenty six isolates of P.aeruginosa were analyzed to study their sensitivity patterns. The presence of the ESBL enzyme was detected by the Phenotypic confirmatory test and the MBL enzyme was detected by the Imipenem – EDTA Double Disk Synergy test.
Result: Out of 126 isolates of P.aeruginosa, 28 (22.22%) were ESBL producers and 10 (7.8%) were MBL producers. None of the isolates showed the coexistence of ESBL and MBL in the same isolate. All the ESBL producing isolates were sensitive to Imipenem, while the MBL producing isolates showed widespread resistance to aminoglycosides, ciprofloxacin and the piperacillin with tazobactum combination.
Conclusion: The present study underlines the unique problem that the presence of ESBL has led to the widespread use of Imipenem, but that the emergence of MBLs and their broad spectrums and unrivalled drug resistance is creating a therapeutic challenge for clinicians and microbiologists. Hence, we suggest that the detection of ESBL and MBL in Pseudomonas aeruginosa should be a routine practice. We recommend a routine surveillance on antibiotic resistance in the hospital.